Prevention of multiple whole blood donations by an individual at the same month through the creation of a national Deferred Donor Registry (DDR)

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBERMUDEZ-FORERO, Maria-Isabel
dc.contributor.authorANZOLA-SAMUDIO, Diego-Alexander
dc.contributor.authorLEVI, Jose-Eduardo
dc.contributor.authorGARCIA-OTALORA, Michel-Andres
dc.date.accessioned2024-02-15T14:53:36Z
dc.date.available2024-02-15T14:53:36Z
dc.date.issued2023
dc.description.abstractIntroduction: The Colombian National Institute of Health administers the National Information System of Haemovigilance (SIHEVI-INS). Today, SIHEVI-INS constitutes a national blood donor and recipient database, which contains a national deferred donor registry (DDR), allowing blood banks to take acceptance or rejection decisions of a potential donor in real time. The study aimed to determine the rate of people who have made more than one whole blood donation monthly in Colombia, violating the national guideline of intervals between donations (three months for men and four for women), since DDR implementation.Methods: We detected the unique personal identification number of people who, in 30 calendar days, made more than one whole blood donation at any of the 83 blood banks set up in Colombia. There were three comparison periods: 01/01/2018-08/31/2019 (launch of SIHEVI-INS and first national feedback); 09/01/2019-12/31/2020 (second feedback) and 01/01/2021-09/30/2022 (massive incorporation of web services).Results: For the first period, blood banks accepted 18.0 donations per 1000 people. There was a rate of 28.8 people/10,000 donations who had donated whole blood twice within 30 days. In the second period, there were 17.0 donations/1000 people and a rate of 2.1 people/10,000 donations (OR:14.0 CI95 %:12.2-16.0). For the last period, there were 18.2 donations/1000 people and a rate of 0.9 individuals/10,000 donations (OR:31.3 CI95 %:26.6-36.9, p < 0.001).Conclusion: DDR reduced by 31 times the acceptance of blood donors who made more than one whole blood donation in the same month. It was necessary to provide periodic feedback and promote web service implementation to reduce this risky behavior.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationTRANSFUSION AND APHERESIS SCIENCE, v.62, n.5, article ID 103767, 6p, 2023
dc.identifier.doi10.1016/j.transci.2023.103767
dc.identifier.eissn1878-1683
dc.identifier.issn1473-0502
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58057
dc.language.isoeng
dc.publisherPERGAMON-ELSEVIER SCIENCE LTDeng
dc.relation.ispartofTransfusion and Apheresis Science
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright PERGAMON-ELSEVIER SCIENCE LTDeng
dc.subjectWhole bloodeng
dc.subjectInter -donation intervaleng
dc.subjectBlood bankeng
dc.subjectInformation systemseng
dc.subject.othercomplicationseng
dc.subject.otherdefinitionseng
dc.subject.othercolombiaeng
dc.subject.wosHematologyeng
dc.titlePrevention of multiple whole blood donations by an individual at the same month through the creation of a national Deferred Donor Registry (DDR)eng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryColômbia
hcfmusp.affiliation.countryisoco
hcfmusp.author.externalBERMUDEZ-FORERO, Maria-Isabel:Inst Nacl Salud INS, Coordinac Red Nacl Bancos Sangre & Serv Transfus, Bogota, Colombia
hcfmusp.author.externalANZOLA-SAMUDIO, Diego-Alexander:Inst Nacl Salud INS, Coordinac Red Nacl Bancos Sangre & Serv Transfus, Bogota, Colombia
hcfmusp.author.externalGARCIA-OTALORA, Michel-Andres:Univ Rosario, Sch Med & Hlth Sci, Publ Hlth Res Grp, Cra 24 63C-69, Bogota, Colombia
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcJOSE EDUARDO LEVI
hcfmusp.description.articlenumber103767
hcfmusp.description.issue5
hcfmusp.description.volume62
hcfmusp.origemWOS
hcfmusp.origem.pubmed37507271
hcfmusp.origem.scopus2-s2.0-85166239921
hcfmusp.origem.wosWOS:001125251700001
hcfmusp.publisher.cityOXFORDeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceBednall TC, 2011, TRANSFUS MED REV, V25, P317, DOI 10.1016/j.tmrv.2011.04.005eng
hcfmusp.relation.referenceBeltran M., 2011, Circular 082 de 2011eng
hcfmusp.relation.referenceBenítez J, 2021, BIOMEDICA, V41, P140, DOI 10.7705/biomedica.6003eng
hcfmusp.relation.referenceBermudez Forero M.I., 2021, Informe Ejecutivo de la Red Nacional Servicios de Transfusion Colombia 2020eng
hcfmusp.relation.referenceBermudez Forero M.I, 2022, Informe Diagnostico Servicios de Transfusion Colombia 2021eng
hcfmusp.relation.referenceBermudez Forero MI., 2022, Informe Anual de la Red Nacional Bancos de Sangre Colombia 2021eng
hcfmusp.relation.referenceBermudez Forero MI., 2021, Informe de Diagnostico de la Red Nacional Bancos de Sangre Colombia 2020eng
hcfmusp.relation.referenceBermudez Forero MI., 2020, Informe Ejecutivo de la Red Nacional Bancos de Sangre Colombia 2019eng
hcfmusp.relation.referenceBermudez Forero MI., 2019, Informe Ejecutivo de la Red Nacional Bancos de Sangre Colombia 2018eng
hcfmusp.relation.referenceBrowne A, 2020, TRANSFUS MED REV, V34, P10, DOI 10.1016/j.tmrv.2019.10.002eng
hcfmusp.relation.referenceCarmona-Fonseca J, 2022, PATHOGENS, V11, DOI 10.3390/pathogens11080893eng
hcfmusp.relation.referenceChew E, 2015, ISBT Sci Ser, V10, P31, DOI [10.1111/voxs.12176, DOI 10.1111/VOXS.12176]eng
hcfmusp.relation.referenceCruz Harold Fabián, 2012, rev.udcaactual.divulg.cient., V15, P19eng
hcfmusp.relation.referenceCuenta de Alto Costo (CAC), 2021, Fondo Colombiano de Enfermedades de Alto Costo., V1, P145eng
hcfmusp.relation.referenceDANE, 2023, Proyecciones de poblacion 2018-2070. DANE Departamento Administrativo Nacional de Estadisticaeng
hcfmusp.relation.referenceDevine DV, 2019, LANCET HAEMATOL, V6, pE492, DOI 10.1016/S2352-3026(19)30162-0eng
hcfmusp.relation.referenceDi Angelantonio E, 2017, LANCET, V390, P2360, DOI 10.1016/S0140-6736(17)31928-1eng
hcfmusp.relation.referenceDomen RE, 1997, INT J QUAL HEALTH C, V9, P35, DOI 10.1093/intqhc/9.1.35eng
hcfmusp.relation.referenceGarcía Gutiérrez Marcela, 2003, Rev Panam Salud Publica, V13, P85eng
hcfmusp.relation.referenceGarcia Otalora M.-A, 2023, Informe de hemovigilancia 2020: Reacciones Adversas a la Donacion (RAD)eng
hcfmusp.relation.referenceGarcia-Otalora M.-A., 2022, Informe de Reacciones adversas a la transfusion 2019eng
hcfmusp.relation.referenceGarcia-Otalora M-A, 2022, Inst Nac De Salud, V1, P102eng
hcfmusp.relation.referenceGarraud O, 2014, BLOOD TRANSFUS-ITALY, V12, pS404, DOI 10.2450/2013.0213-12eng
hcfmusp.relation.referenceGobierno de Colombia, 2012, Ley 1581 de 2012eng
hcfmusp.relation.referenceGobierno de Colombia, 2008, Ley 1266 de 2008eng
hcfmusp.relation.referenceGoldman M, 2016, VOX SANG, V110, P185, DOI 10.1111/vox.12323eng
hcfmusp.relation.referenceHerrera G, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006419eng
hcfmusp.relation.referenceHerrera-Hernandez A., 2019, Anexo tecnico 4 circular 082 de 2011eng
hcfmusp.relation.referenceHolland PV, 2008, TRANSFUSION, V48, P6, DOI 10.1111/j.1537-2995.2007.01558.xeng
hcfmusp.relation.referenceInternational Haemoviglance Network, 2019, Current Members.eng
hcfmusp.relation.referenceISBT I, 2012, An Effective Tool for Improving Transfusion Safety, V1eng
hcfmusp.relation.referenceKaptoge S, 2019, LANCET HAEMATOL, V6, pE510, DOI 10.1016/S2352-3026(19)30106-1eng
hcfmusp.relation.referenceMayorga Mogollon L.E, 2022, Informe de Evento. Hepatitis B, C y Coinfeccion B-D. Periodo epidemiologico XIIeng
hcfmusp.relation.referenceMayorga Mogollon L.E, 2022, VIH SIDA PERIODO EPIeng
hcfmusp.relation.referenceMinisterio de Salud, 1993, Decreto 1571 de 1993.eng
hcfmusp.relation.referenceMinisterio de Salud, Resolucion 1738 de 1995 1995eng
hcfmusp.relation.referenceMinisterio de Salud y Proteccion Social, Resolucion 437 de 2014 2014eng
hcfmusp.relation.referenceMinisterio de Salud y Proteccion Social, 2016, Decreto numero 780 de 2016.eng
hcfmusp.relation.referenceMinisterio de Salud y Proteccion Social, 2018, Resolucion 3212eng
hcfmusp.relation.referenceMora-Salamanca AF, 2020, INT J INFECT DIS, V97, P81, DOI 10.1016/j.ijid.2020.05.051eng
hcfmusp.relation.referencePPTA. National Donor Deferral Registry (NDDR), 2023, About useng
hcfmusp.relation.referenceRamoa A, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/6183468eng
hcfmusp.relation.referenceRegistraduria, Cedula de ciudadania. Cedula de ciudadania.eng
hcfmusp.relation.referenceSchipperus MR, 2019, TRANSFUSION, V59, P2482, DOI 10.1111/trf.15389eng
hcfmusp.relation.referenceSherwood William C., 1993, Transfusion Medicine Reviews, V7, P121, DOI 10.1016/S0887-7963(93)70131-5eng
hcfmusp.relation.referenceuenta de Alto Costo (CAC), 2021, Fondo Colombiano de Enfermedades de Alto Costo., V1, P86eng
hcfmusp.relation.referenceUrbina A, 2022, TRANSFUS APHER SCI, V61, DOI 10.1016/j.transci.2021.103340eng
hcfmusp.relation.referenceWorld Health Organization, 2016, A guide to establishing a national haemovigilance system., V1eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication4ca67ecb-e5bc-4ad6-86ed-bea07644d7a8
relation.isAuthorOfPublication.latestForDiscovery4ca67ecb-e5bc-4ad6-86ed-bea07644d7a8
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/52